biotech · Relapsed/Refractory Multiple Myeloma · Respiratory Distress Syndrome, Adult · INKT
MiNK Therapeutics
MiNK Therapeutics patent portfolio — 6 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.
Company details
- Status
- Public
- HQ
- NEW YORK, NY, SE
- Founded
- 2012
- Employees
- 9
- Programs
- 3
- Drugs
- 1
- Patents
- 6
MiNK Therapeutics patents
6 pharmaceutical patents indexed for MiNK Therapeutics. 0 expire within 24 months.
MiNK Therapeutics has 6 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.
Patent portfolio
-
US 12419955
Method for efficiently infecting human natural killer cells and other immune cells with pseudovirus
granted -
US 12391741
T cell receptors that bind to mixed lineage leukemia (MLL)-specific phosphopeptides and methods of use thereof
granted -
US 11898165
Engineered host cells and methods of use thereof
granted -
US 11718658
T cell receptors that bind to mixed lineage leukemia (MLL)-specific phosphopeptides and methods of use thereof
granted -
US 11613764
T cell receptors that bind to NY-ESO-1 and methods of use thereof
granted -
US 9943496
Dietary supplement based on ethyl ferulate
granted
Frequently asked questions
How many patents does MiNK Therapeutics have?
6 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do MiNK Therapeutics patents expire?
0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.